Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22
Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.
Stocks · News reference
Evommune shares are trading lower after the company announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis. The experimental drug failed to reach both its primary and secondary endpoints across all tested dose levels, and the firm decided that it would not move EVO756 forward for atopic dermatitis.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21
Evommune Halts Atopic Dermatitis Program Following Trial Failure
Evommune halts EVO756 development in atopic dermatitis following a Phase 2b trial failure, shifting focus to its EVO301 candidate.